<DOC>
	<DOCNO>NCT03044873</DOCNO>
	<brief_summary>The study assess effect coadministration multiple dose BMS-986165 systemic exposure rosuvastatin healthy participant .</brief_summary>
	<brief_title>Effect BMS-986165 Pharmacokinetics Rosuvastatin</brief_title>
	<detailed_description />
	<mesh_term>Autoimmune Diseases</mesh_term>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>1 . Signed Informed Consent 2 . Healthy male female participant ( childbearing potential ) determine clinically significant deviation normal medical history , physical exam , ECGs , clinical laboratory determination 3 . Subjects body mass index 18 32 kg/m2 , inclusive . 4 . Women participant must document proof childbearing potential . 5 . Men sexually active WOCBP must agree follow instruction method ( ) highly effective contraception duration study treatment ( ) plus 5 halflives BMS986165 ( 4 day ) plus 90 day ( duration sperm turnover ) total 94 day post BMS986165 treatment . In addition , male participant must willing refrain sperm donation time . 1 . History allergy BMS986165 , rosuvastatin , related compound , myalgia rhabdomyolysis take rosuvastatin related compound drug allergy 2 . Any significant acute chronic medical illness , active TB require treatment document latent TB within previous 3 year , current recent gastrointestinal disease , current recent history nausea , vomit , constipation irregular bowel movement 3 . History chronic headache , syncope , orthostatic instability , recurrent dizziness , biliary disorder , druginduced acne rash , fibromyalgia , neutropenia thrombocytopenia 4 . Smokers currently smoke , recent drug alcohol abuse , blood transfusion within 4 week study treatment administration , current skin finding could interfere interpretation study Other protocol define inclusion/exclusion criterion could apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>